deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT04394650

A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase I, Multi Center, Open Label Study of CC-98633, BCMA Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma

Sponsor: Juno Therapeutics, a Subsidiary of Celgene

Conditions Multiple Myeloma
Interventions CC-98633
Updated 16 times since 2020 Last updated: Jul 24, 2024 Started: Aug 18, 2020 Primary completion: Jul 3, 2024 Completion: Jul 3, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by Juno Therapeutics, a Subsidiary of Celgene and has accumulated 16 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Feb 2022 · 4 months · monthly snapshot~Feb 2022 – ~Jun 2022 · 4 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Apr 2023 · 5 months · monthly snapshot~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  3. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Apr 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Nov 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

▶ Show 11 earlier versions

  1. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1

  2. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  3. Feb 2022 — Jun 2022 [monthly]

    Recruiting PHASE1

  4. Oct 2021 — Feb 2022 [monthly]

    Recruiting PHASE1

  5. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

  6. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  7. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

  8. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  9. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE1

  10. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  11. Jun 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Juno Therapeutics, a Subsidiary of Celgene
Data source: Juno Therapeutics, a Subsidiary of Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations